All lobbying filings

RK STRATEGIES, INC.

RK STRATEGIES, INC. filed a Q3 report for CLEARMIND MEDICINE, INC on October 20, 2025, reporting $10,000 in lobbying income.

Lobbying for CLEARMIND MEDICINE, INC · Developer of Psychedelics Medicines

All filings by RK STRATEGIES, INC. · Everything CLEARMIND MEDICINE, INC has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$10,000

What the client paid this registrant for the period.

Client based in

British Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

Psychedelic Legislation H.R.2623, Innovative Therapies Centers of Excellence Act of 2025

Defense

Psychedelic Legislation H.R.2623, Innovative Therapies Centers of Excellence Act of 2025 H.R. 3838, the Streamlining Procurement for Effective Execution and Delivery Act

Alcohol and Drug Abuse

H.R. 3838, the Streamlining Procurement for Effective Execution and Delivery (SPEED) Act H.R.2623, Innovative Therapies Centers of Excellence Act of 2025 Issues Related to Psychedelic Medicines

Veterans

H.R.2623, Innovative Therapies Centers of Excellence Act of 2025

Bills named in this filing 2

H.R. 2623
Innovative Therapies Centers of Excellence Act of 2025
H.R. 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.